Stock to Watch : GENZ for Continued Downside

Genzyme Corp. (GENZ) made headlines on Friday after a late-stage trial showed its drug tolevar (which was hoped to be a treatment for bacteria-induced diarrhea) was not any more effective than what is already in use for standard treatment. I'd been keeping an eye on GENZ for a few weeks now for a longer term short because it's already had a couple of tests of the lower end of a larger weekly and monthly descending triangle and this news now creates a third test and the most likely breaking point.